Zacks Investment Research
26 Jun 2026, 15:45 UTC · 2h ago
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
26 Jun 2026, 15:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Ionis Pharmaceuticals has signed a license agreement with Recordati for the ex-U.S. development and marketing of zilganersen. — Provides immediate cash flow via a $30M upfront payment and secures future revenue through royalties and milestones.
+0.40The FDA is currently reviewing zilganersen for the treatment of Alexander disease (AxD), with a decision expected by September 22, 2026. — The approval of a drug for a disease with no current disease-modifying medicines represents significant potential market capture.
+0.30A pivotal late-stage study for zilganersen met its primary endpoint, showing statistically significant stabilization in gait speed for patients. — Positive clinical data increases the probability of regulatory approval and commercial success.
+0.20Continue reading
6 related stories
Search tags
If approved, zilganersen will mark Ionis' first commercial entry into the neurology space. — Diversifies the company's commercial portfolio and expands its therapeutic reach into a new medical sector.
+0.10Which stocks this story touches
The company signed a lucrative licensing agreement and has positive late-stage study results for its drug zilganersen.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
